Information Hub

Clinical News

2020-03-23

Promising treatment outcome of molecular matched therapy in advanced salivary gland carcinoma

In a phase IIa study (MyPathway), advanced salivary gland carcinoma were treated with molecular matched therapy based on their molecular characteristics, and the results showed a promising efficacy.

Source:

Annals of Oncology

2020-03-23

Neratinib plus fulvestrant showed promising anti-tumor activities in patients with HER2-mutant breast cancer

HER2 mutation is one of the acquired resistance mechanisms in breast cancer. In a phase II SUMMIT study, HER2-mutant breast cancers were sensitive to neratinib treatment. Besides, the resistance mechanisms of neratinib were also studied.

Source:

Cancer Discov.

2020-03-23

FDA grants breakthrough therapy designation to JNJ-6372 in non-small cell lung cancer

The FDA granted breakthrough therapy designation to JNJ-6372, an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody, to treat metastastic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

Source:

J Clin Oncol.

2020-02-27

Genetic testing results revealed the resistance mechanisms of DNA-damaging therapies in breast cancer

Homologous recombination restoration, including reversion and nonreversion mechanisms in BRCA1/2 will cause drug resistance in BRCA1/2-mutation breast cancer patients who received PARP inhibitors or platinum chemotherapy as study shows.

Source:

Annals of Oncology

2020-02-27

Combination of cobimetinib and vemurafenib showed great anti-tumor activities in CRC patients with a BRAF V600E mutation

In a phase II basket trial (TAPUR), cobimetinib and vemurafenib were used in combination to treat CRC patients with BRAF V600E mutations. This combination showed evidence of anti-tumor activities in this study.

Source:

J Clin Oncol

2020-02-27

Talazoparib demonstrated clinical activity in men with DNA damage repair mutations and metastatic castration-resistant prostate cancer

In a phase II trial (TALAPRO-1), talazoparib demonstrated encouraging antitumor activity in metastatic castration-resistant prostate cancer with DNA damage repair mutations.

Source:

J Clin Oncol

2020-01-22

FDA approved trastuzumab deruxtecan for HER2-positive breast cancer

Trastuzumab deruxtecan received FDA approval for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.

Source:

Modi S. et al. N Engl J Med. 2019

2020-01-22

Veliparib plus carboplatin and paclitaxel showed clinically meaningful benefit in HER2 negative breast cancer patients with BRCA mutation

A combination of veliparib, carboplatin, and paclitaxel significantly improve the PFS of breast cancer patients who had low HER2 expression and a BRCA mutation in phase 3 BROCADE3 study.

Source:

Annals of Oncology (2019)

2020-01-22

Tucatinib triplet reduces risk of death in metastatic HER2-positive breast cancer

HER2-positive breast cancer patients have limited treatment options after therapy with multiple HER2-targeted agents. In the HER2CLIMB trial, the addition of tucatinib to trastuzumab and capecitabine showed clinicl benefit in heavily pretreated HER2-posit

Source:

N Engl J Med. 2019

2019-12-30

A new targeted therapy for advanced gastrointestinal stromal tumors (GIST)

Ripretinib is a novel tyrosine kinase inhibitor that was designed to target KIT and PDGFRα-mutated kinase. A phase III study (INVICTUS) showed that ripretinib improved PFS and OS compared with placebo in patients with GIST progressed with more than three

Source:

2019 ESMO congress

青娱极品盛宴国产分类-亚洲 欧美 日韩 国产 制服-国产爆乳合集在线视频,五月色婷婷,久久热在线视频,免费网站看v片在线薰衣草